An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir

An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir

Abstract Background The World Health Organisation approved boosted atazanavir as a preferred second line protease inhibitor in 2010. This is as an alternative to the current boosted lopinavir. Atazanavir has a lower genetic barrier than lopinavir. We compared the virological outcomes of patients dur...

Full description

Bibliographic Details
Main Authors: Eva Agnes Odongpiny Laker, Maria Sarah Nabaggala, Arvind Kaimal, Damalie Nalwanga, Barbara Castelnuovo, Abdu Musubire, Agnes Kiragga, Mohammed Lamorde, Rosalind Parkes- Ratanshi
Format: Article
Language:English
Published: BMC 2019-03-01
Series:BMC Infectious Diseases
Subjects:
Second-line antiretroviral
First-line failure
Atazanavir
Lopinavir
Online Access:http://link.springer.com/article/10.1186/s12879-019-3907-5

Internet

http://link.springer.com/article/10.1186/s12879-019-3907-5

Similar Items